Angiogenesis, Basic Mechanisms, and Role in Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer: Emerging Perspectives

Volumn , Issue , 2003, Pages 81-100

  Tassi, Elena ^a   Wellstein, Anton ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77958454324     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012239990-9/50008-4     Document Type: Chapter

References (286)

1. Renan M.J. How many mutations are required for tumorigenesis? Implications from human cancer data. Mol. Carcinog. 1993, 7:139.
2. Voravud N., Charuruks N., Mutirangura A. Squamous cell carcinoma of head and neck. J. Med. Assoc. Thai 1997, 80:207.
3. Shao X., Tandon R., Samara G., Kanki H., Yano H., Close L.G., Parsons R., Sato T. Mutational analysis of the PTEN gene in head and neck squamous cell carcinoma. Int. J. Cancer 1998, 77:684.
4. Nagai M.A. Genetic alterations in head and neck squamous cell carcinomas. Braz. J. Med. Biol. Res. 1999, 32:897.
5. Field J.K. Oncogenes and tumour-suppressor genes in squamous cell carcinoma of the head and neck. Eur. J. Cancer B Oral Oncol. 1992, 28B:67.
6. Shackleford G.M., MacArthur C.A., Kwan H.C., Varmus H.E. Mouse mammary tumor virus infection accelerates mammary carcinogenesis in Wnt-1 transgenic mice by insertional activation of int-2/Fgf-3 and hst/Fgf-4. Proc. Natl. Acad. Sci. USA 1993, 90:740.
7. Wellstein A., Zugmaier G., Califano J.A.D., Kern F., Paik S., Lippman M.E. Tumor growth dependent on Kaposi's sarcoma-derived fibroblast growth factor inhibited by pentosan polysulfate. J. Natl. Cancer Inst. 1991, 83:716.
8. Costa M., Danesi R., Agen C., Di Paolo A., Basolo F., Del Bianchi S., Del Tacca M. MCF-10A cells infected with the int-2 oncogene induce angiogenesis in the chick chorioallantoic membrane and in the rat mesentery. Cancer Res. 1994, 54:9.
9. Muller D., Millon R., Velten M., Bronner G., Jung G., Engelmann A., Flesch H., Eber M., Methlin G., Abecassis J. Amplification of 11q13 DNA markers in head and neck squamous cell carcinomas: Correlation with clinical outcome. Eur. J. Cancer 1997, 33:2203.
10. Williams M.E., Gaffey M.J., Weiss L.M., Wilczynski S.P., Schuuring E., Levine P.A. Chromosome 11Q13 amplification in head and neck squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 1993, 119:1238.
11. Jin Y., Mertens F., Mandahl N., Heim S., Olegard C., Wennerberg J., Biorklund A., Mitelman F. Chromosome abnormalities in eighty-three head and neck squamous cell carcinomas: Influence of culture conditions on karyotypic pattern. Cancer Res. 1993, 53:2140.
12. Cowan J.M., Beckett M.A., Weichselbaum R.R. Chromosome changes characterizing in vitro response to radiation in human squamous cell carcinoma lines. Cancer Res. 1993, 53:5542.
13. Van Dyke D.L., Worsham M.J., Benninger M.S., Krause C.J., Baker S.R., Wolf G.T., Drumheller T., Tilley B.C., Carey T.E. Recurrent cytogenetic abnormalities in squamous cell carcinomas of the head and neck region. Genes Chromosomes Cancer 1994, 9:192.
14. Ransom D.T., Leonard J.H., Kearsley J.H., Turbett G.R., Heel K., Sosars V., Hayward N.K., Bishop J.F. Loss of heterozygosity studies in squamous cell carcinomas of the head and neck. Head Neck 1996, 18:248.
15. Califano J., van der Riet P., Westra W., Nawroz H., Clayman G., Piantadosi S., Corio R., Lee D., Greenberg B., Koch W., Sidransky D. Genetic progression model for head and neck cancer: Implications for field cancerization. Cancer Res. 1996, 56:2488.
16. Folkman J., Shing Y. Angiogenesis. J. Biol. Chem. 1992, 267:10931.
17. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nature Med. 2000, 6:389.
18. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353.
19. Salamonsen L.A., Woolley D.E. Matrix metalloproteinases in normal menstruation. Hum. Reprod. 1996, 11(Suppl. 2):124.
20. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249.
21. Blood C.H., Zetter B.R. Tumor interactions with the vasculature: Angiogenesis and tumor metastasis. Biochim. Biophys. Acta 1990, 1032:89.
22. Risau W. Development and differentiation of endothelium. Kidney Int. Suppl. 1998, 67:S3.
23. Helmlinger G., Yuan F., Dellian M., Jain R.K. Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation. Nature Med. 1997, 3:177.
24. Maniotis A.J., Folberg R., Hess A., Seftor E.A., Gardner L.M., Pe'er J., Trent J.M., Meltzer P.S., Hendrix M.J. Vascular channel formation by human melanoma cells in vivo and in vitro: Vasculogenic mimicry. Am. J. Pathol. 1999, 155:739.
25. Baish J.W., Jain R.K. Fractals and cancer. Cancer Res. 2000, 60:3683.
26. Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., Jain R.K. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc. Natl. Acad. Sci. USA 1998, 95:4607.
27. Hashizume H., Baluk P., Morikawa S., McLean J.W., Thurston G., Roberge S., Jain R.K., McDonald D.M. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 2000, 156:1363.
28. Dvorak H.F., Nagy J.A., Feng D., Brown L.F., Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr. Top. Microbiol. Immunol. 1999, 237:97.
29. Benjamin L.E., Golijanin D., Itin A., Pode D., Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 1999, 103:159.
30. Folberg R., Hendrix M.J., Maniotis A.J. Vasculogenic mimicry and tumor angiogenesis. Am. J. Pathol. 2000, 156:361.
31. Goldman E. The growth of malignant disease in man and the lower animals with special reference to the vascular system. Lancet 1907, 2:1236.
32. Ide A.G., Baker N.H., S.L.W. Vascularization of the Brown-Pearce rabbit epithelioma transplant as seen in the transparent ear chamber. Am. J. Radiol. 1939, 42:891.
33. Greenblatt M., Shubi P. Tumor angiogenesis: Transfilter diffusion studies in the hamster by the transparent chamber technique. J. Natl. Cancer Inst. 1968, 41:111.
34. Ehrmann R.L., Knoth M. Choriocarcinoma. Transfilter stimulation of vasoproliferation in the hamster cheek pouch. Studies by light and electron microscopy. J. Natl. Cancer Inst. 1968, 41:1329.
35. Folkman J. Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med. 1971, 285:1182.
36. Folkman J. Anti-angiogenesis: New concept for therapy of solid tumors. Ann. Surg. 1972, 175:409.
37. Folkman J., Merler E., Abernathy C., Williams G. Isolation of a tumor factor responsible or angiogenesis. J. Exp. Med. 1971, 133:275.
38. Folkman J. Proceedings: Tumor angiogenesis factor. Cancer Res. 1974, 34:2109.
39. Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 1985, 315:115.
40. Kandel J., Bossy-Wetzel E., Radvanyi F., Klagsbrun M., Folkman J., Hanahan D. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 1991, 66:1095.
41. Arbeit J.M., Munger K., Howley P.M., Hanahan D. Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice. J. Virol. 1994, 68:4358.
42. Arbeit J.M. Transgenic models of epidermal neoplasia and multistage carcinogenesis. Cancer Surv. 1996, 26:7.
43. Arbeit J.M., Olson D.C., Hanahan D. Upregulation of fibroblast growth factors and their receptors during multi-stage epidermal carcinogenesis in K14-HPV16 transgenic mice. Oncogene 1996, 13:1847.
44. Brown L.F., Berse B., Jackman R.W., Tognazzi K., Guidi A.J., Dvorak H.F., Senger D.R., Connolly J.L., Schnitt S.J. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol. 1995, 26:86.
45. Guidi A.J., Fischer L., Harris J.R., Schnitt S.J. Microvessel density and distribution in ductal carcinoma in situ of the breast. J. Natl. Cancer Inst. 1994, 86:614.
46. Weidner N., Folkman J., Pozza F., Bevilacqua P., Allred E.N., Moore D.H., Meli S., Gasparini G. Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl. Cancer Inst. 1992, 84:1875.
47. Smith-McCune K.K., Weidner N. Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Res. 1994, 54:800.
48. Guidi A.J., Abu-Jawdeh G., Berse B., Jackman R.W., Tognazzi K., Dvorak H.F., Brown L.F. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J. Natl. Cancer Inst. 1995, 87:1237.
49. Folkman J., D'Amore P.A. Blood vessel formation: What is its molecular basis?. Cell 1996, 87:1153.
50. Zagzag D., Hooper A., Friedlander D.R., Chan W., Holash J., Wiegand S.J., Yancopoulos G.D., Grumet M. In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis. Exp. Neurol. 1999, 159:391.
51. Holash J., Maisonpierre P.C., Compton D., Boland P., Alexander C.R., Zagzag D., Yancopoulos G.D., Wiegand S.J. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999, 284:1994.
52. Yancopoulos G.D., Davis S., Gale N.W., Rudge J.S., Wiegand S.J., Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000, 407:242.
53. Wesseling P., van der Laak J.A., de Leeuw H., Ruiter D.J., Burger P.C. Quantitative immunohistological analysis of the microvasculature in untreated human glioblastoma multiforme: Computer-assisted image analysis of whole-tumor sections. J. Neurosurg. 1994, 81:902.
54. Holmgren L., O'Reilly M.S., Folkman J. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med. 1995, 1:149.
55. Pezzella F., Pastorino U., Tagliabue E., Andreola S., Sozzi G., Gasparini G., Menard S., Gatter K.C., Harris A.L., Fox S., Buyse M., Pilotti S., Pierotti M., Rilke F. Non-small-cell lung carcinoma tumor growth without morphological evidence of neoangiogenesis. Am. J. Pathol. 1997, 151:1417.
56. Srivastava A., Laidler P., Hughes L.E., Woodcock J., Shedden E.J. Neovascularization in human cutaneous melanoma: A quantitative morphological and Doppler ultrasound study. Eur. J. Cancer Clin. Oncol. 1986, 22:1205.
57. Srivastava A., Laidler P., Davies R.P., Horgan K., Hughes L.E. The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma: A quantitative histologic study. Am. J. Pathol. 1988, 133:419.
58. Weidner N., Semple J.P., Welch W.R., Folkman J. Tumor angiogenesis and metastasis: Correlation in invasive breast carcinoma. N. Engl. J. Med. 1991, 324:1.
59. Weidner N., Carroll P.R., Flax J., Blumenfeld W., Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol. 1993, 143:401.
60. Folkman J. Seminars in medicine of the Beth Israel Hospital, Boston: Clinical applications of research on angiogenesis. N. Engl. J. Med. 1995, 333:1757.
61. Macchiarini P., Fontanini G., Hardin M.J., Squartini F., Angeletti C.A. Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet 1992, 340:145.
62. Wakui S., Furusato M., Itoh T., Sasaki H., Akiyama A., Kinoshita I., Asano K., Tokuda T., Aizawa S., Ushigome S. Tumour angiogenesis in prostatic carcinoma with and without bone marrow metastasis: A morphometric study. J. Pathol. 1992, 168:257.
63. Ikinger U., Terwey B., Wurster K., Manegold C., Moehring K. Vascularization of malignant testicular tumors. Urology 1985, 26:41.
64. Moreira L.F., Iwagaki H., Hizuta A., Sakagami K., Orita K. Outcome in patients with early colorectal carcinoma. Br. J. Surg. 1992, 79:436.
65. Petruzzelli G.J., Snyderman C.H., Johnson J.T., Myers E.N. Angiogenesis induced by head and neck squamous cell carcinoma xenografts in the chick embryo chorioallantoic membrane model. Ann. Otol. Rhinol. Laryngol. 1993, 102:215.
66. Mukai K., Rosai J., Burgdorf W.H. Localization of factor VIII-related antigen in vascular endothelial cells using an immunoperoxidase method. Am. J. Surg. Pathol. 1980, 4:273.
67. Holthofer H., Virtanen I., Kariniemi A.L., Hormia M., Linder E., Miettinen A. Ulex europaeus I lectin as a marker for vascular endothelium in human tissues. Lab. Invest. 1982, 47:60.
68. Ramani P., Birch B.R., Harland S.J., Parkinson M.C. Evaluation of endothelial markers in detecting blood and lymphatic channel invasion in pT1 transitional carcinoma of bladder. Histopathology 1991, 19:551.
69. Delides G.S., Venizelos J., Revesz L. Vascularization and curability of stage III and IV nasopharyngeal tumors. J. Cancer. Res. Clin. Oncol. 1988, 114:321.
70. Zatterstrom U.K., Brun E., Willen R., Kjellen E., Wennerberg J. Tumor angiogenesis and prognosis in squamous cell carcinoma of the head and neck. Head Neck 1995, 17:312.
71. Carrau R.L., Barnes E.L., Snyderman C.H., Petruzzelli G., Kachman K., Rueger R., D'Amico F., Johnson J.T. Tumor angiogenesis as a predictor of tumor aggressiveness and metastatic potential in squamous cell carcinoma of the head and neck. Invasion Metastasis 1995, 15:197.
72. Gasparini G., Weidner N., Maluta S., Pozza F., Boracchi P., Mezzetti M., Testolin A., Bevilacqua P. Intratumoral microvessel density and p53 protein: Correlation with metastasis in head-and-neck squamous-cell carcinoma. Int. J. Cancer 1993, 55:739.
73. Beatrice F., Cammarota R., Giordano C., Corrado S., Ragona R., Sartoris A., Bussolino F., Valente G. Angiogenesis: Prognostic significance in laryngeal cancer. Anticancer Res. 1998, 18:4737.
74. Williams J.K., Carlson G.W., Cohen C., Derose P.B., Hunter S., Jurkiewicz M.J. Tumor angiogenesis as a prognostic factor in oral cavity tumors. Am. J. Surg. 1994, 168:373.
75. Leedy D.A., Trune D.R., Kronz J.D., Weidner N., Cohen J.I. Tumor angiogenesis, the p53 antigen, and cervical metastasis in squamous carcinoma of the tongue. Otolaryngol. Head Neck Surg. 1994, 111:417.
76. Alcalde R.E., Shintani S., Yoshihama Y., Matsumura T. Cell proliferation and tumor angiogenesis in oral squamous cell carcinoma. Anticancer Res. 1995, 15:1417.
77. Penfold C.N., Partridge M., Rojas R., Langdon J.D. The role of angiogenesis in the spread of oral squamous cell carcinoma. Br. J. Oral. Maxillofac. Surg. 1996, 34:37.
78. Gleich L.L., Biddinger P.W., Pavelic Z.P., Gluckman J.L. Tumor angiogenesis in T1 oral cavity squamous cell carcinoma: Role in predicting tumor aggressiveness. Head Neck 1996, 18:343.
79. Gleich L.L., Biddinger P.W., Duperier F.D., Gluckman J.L. Tumor angiogenesis as a prognostic indicator in T2-T4 oral cavity squamous cell carcinoma: A clinical-pathologic correlation. Head Neck 1997, 19:276.
80. Pazouki S., Chisholm D.M., Adi M.M., Carmichael G., Farquharson M., Ogden G.R., Schor S.L., Schor A.M. The association between tumour progression and vascularity in the oral mucosa. J. Pathol. 1997, 183:39.
81. Albo D., Granick M.S., Jhala N., Atkinson B., Solomon M.P. The relationship of angiogenesis to biological activity in human squamous cell carcinomas of the head and neck. Ann. Plast. Surg. 1994, 32:588.
82. Kessler D.A., Langer R.S., Pless N.A., Folkman J. Mast cells and tumor angiogenesis. Int. J. Cancer 1976, 18:703.
83. Dray T.G., Hardin N.J., Sofferman R.A. Angiogenesis as a prognostic marker in early head and neck cancer. Ann. Otol. Rhinol. Laryngol. 1995, 104:724.
84. Stone J., Itin A., Alon T., Pe'er J., Gnessin H., Chan-Ling T., Keshet E. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J. Neurosci. 1995, 15:4738.
85. Alon T., Hemo I., Itin A., Pe'er J., Stone J., Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nature Med. 1995, 1:1024.
86. Benjamin L.E., Hemo I., Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF- B and VEGF. Development 1998, 125:1591.
87. Bikfalvi A., Klein S., Pintucci G., Rifkin D.B. Biological roles of fibroblast growth factor-2. Endocr. Rev. 1997, 18:26.
88. Powers C.J., McLeskey S.W., Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr. Relat. Cancer 2000, 7:165.
89. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306.
90. Ferrara N., Keyt B. Vascular endothelial growth factor: Basic biology and clinical implications. Exs. 1997, 79:209.
91. Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 1997, 18:4.
92. McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist 2000, 5:3.
93. Shemirani B., Crowe D.L. Head and neck squamous cell carcinoma lines produce biologically active angiogenic factors. Oral Oncol. 2000, 36:61.
94. Benefield J., Petruzzelli G.J., Fowler S., Taitz A., Kalkanis J., Young M.R. Regulation of the steps of angiogenesis by human head and neck squamous cell carcinomas. Invasion Metastasis 1996, 16:291.
95. Petruzzelli G.J., Benefield J., Taitz A.D., Fowler S., Kalkanis J., Scobercea S., West D., Young M.R. Heparin-binding growth factor(s) derived from head and neck squamous cell carcinomas induce endothelial cell proliferations. Head Neck 1997, 19:576.
96. Thomas G.R., Tubb E.E., Sessions R.B., Cullen K.J. Growth factor mRNA expression in human head and neck malignant tumors. Arch. Otolaryngol. Head Neck Surg. 1993, 119:1247.
97. Alcalde R.E., Terakado N., Otsuki K., Matsumura T. Angiogenesis and expression of platelet-derived endothelial cell growth factor in oral squamous cell carcinoma. Oncology 1997, 54:324.
98. Cordon-Cardo C., Vlodavsky I., Haimovitz-Friedman A., Hicklin D., Fuks Z. Expression of basic fibroblast growth factor in normal human tissues. Lab. Invest. 1990, 63:832.
99. Baird A., Klagsbrun M. The fibroblast growth factor family. Cancer Cells 1991, 3:239.
100. Morrison R.S., Gross J.L., Herblin W.F., Reilly T.M., LaSala P.A., Alterman R.L., Moskal J.R., Kornblith P.L., Dexter D.L. Basic fibroblast growth factor-like activity and receptors are expressed in a human glioma cell line. Cancer Res. 1990, 50:2524.
101. Gross J.L., Morrison R.S., Eidsvoog K., Herblin W.F., Kornblith P.L., Dexter D.L. Basic fibroblast growth factor: A potential autocrine regulator of human glioma cell growth. J. Neurosci. Res. 1990, 27:689.
102. Luqmani Y.A., Graham M., Coombes R.C. Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues. Br. J. Cancer 1992, 66:273.
103. Nanus D.M., Schmitz-Drager B.J., Motzer R.J., Lee A.C., Vlamis V., Cordon-Cardo C., Albino A.P., Reuter V.E. Expression of basic fibroblast growth factor in primary human renal tumors: Correlation with poor survival. J. Natl. Cancer Inst. 1993, 85:1597.
104. Yamanaka Y., Friess H., Buchler M., Beger H.G., Uchida E., Onda M., Kobrin M.S., Korc M. Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res. 1993, 53:5289.
105. Schultz-Hector S., Haghayegh S. Beta-fibroblast growth factor expression in human and murine squamous cell carcinomas and its relationship to regional endothelial cell proliferation. Cancer Res. 1993, 53:1444.
106. Shing Y., Folkman J., Sullivan R., Butterfield C., Murray J., Klagsbrun M. Heparin affinity: Purification of a tumorderived capillary endothelial cell growth factor. Science 1984, 223:1296.
107. Folkman J., Klagsbrun M. Angiogenic factors. Science 1987, 235:442.
108. Basilico C., Moscatelli D. The FGF family of growth factors and oncogenes. Adv. Cancer Res. 1992, 59:115.
109. Yayon A., Klagsbrun M., Esko J.D., Leder P., Ornitz D.M. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 1991, 64:841.
110. Klagsbrun M., Baird A. A dual receptor system is required for basic fibroblast growth factor activity. Cell 1991, 67:229.
111. Rapraeger A.C., Krufka A., Olwin B.B. Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science 1991, 252:1705.
112. Rapraeger A.C., Guimond S., Krufka A., Olwin B.B. Regulation of heparan sulfate in fibroblast growth factor signaling. Methods Enzymol. 1994, 245:219.
113. Mignatti P., Morimoto T., Rifkin D.B. Basic fibroblast growth factor, a protein devoid of secretory signal sequence, is released by cells via a pathway independent of the endoplasmic reticulum-Golgi complex. J. Cell Physiol. 1992, 151:81.
114. McNeil P.L., Muthukrishnan L., Warder E., D'Amore P.A. Growth factors are released by mechanically wounded endothelial cells. J. Cell Biol. 1989, 109:811.
115. Bashkin P., Doctrow S., Klagsbrun M., Svahn C.M., Folkman J., Vlodavsky I. Basif fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules. Biochemistry 1989, 28:1737.
116. Saksela O., Rifkin D.B. Release of basic fibroblast growth factor-neparan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity. J. Cell Biol. 1990, 110:767.
117. Buczek-Thomas J.A., Nugent M.A. Elastase-mediated release of heparan sulfate proteoglycans from pulmonary fibroblast cultures: A mechanism for basic fibroblast growth factor (bFGF) release and attenuation of bfgf binding following elastase-induced injury. J. Biol. Chem. 1999, 274:25167.
118. Wu D.Q., Kan M.K., Sato G.H., Okamato T., Sato J.D. Characterization and molecular cloning of a putative binding protein for heparin-binding growth factors. J. Biol. Chem. 1991, 266:16778.
119. Czubayko F., Smith R.V., Chung H.C., Wellstein A. Tumor growth and angiogenesis induced by a secreted binding protein for fibroblast growth factors. J. Biol. Chem. 1994, 269:28243.
120. Kurtz A., Wang H.L., Darwiche N., Harris V., Wellstein A. Expression of a binding protein for FGF is associated with epithelial development and skin carcinogenesis. Oncogene 1997, 14:2671.
121. Czubayko F., Liaudet-Coopman E.D., Aigner A., Tuveson A.T., Berchem G.J., Wellstein A. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nature Med. 1997, 3:1137.
122. Schulze-Osthoff K., Risau W., Vollmer E., Sorg C. In situ detection of basic fibroblast growth factor by highly specific antibodies. Am. J. Pathol. 1990, 137:85.
123. Takahashi J.A., Mori H., Fukumoto M., Igarashi K., Jaye M., Oda Y., Kikuchi H., Hatanaka M. Gene expression of fibroblast growth factors in human gliomas and meningiomas: Demonstration of cellular source of basic fibroblast growth factor mRNA and peptide in tumor tissues. Proc. Natl. Acad. Sci. USA 1990, 87:5710.
124. Zagzag D., Miller D.C., Sato Y., Rifkin D.B., Burstein D.E. Immunohistochemical localization of basic fibroblast growth factor in astrocytomas. Cancer Res. 1990, 50:7393.
125. Statuto M., Ennas M.G., Zamboni G., Bonetti F., Pea M., Bernardello F., Pozzi A., Rusnati M., Gualandris A., Presta M. Basic fibroblast growth factor in human pheochromocytoma: A biochemical and immunohistochemical study. Int. J. Cancer 1993, 53:5.
126. Ohtani H., Nakamura S., Watanabe Y., Mizoi T., Saku T., Nagura H. Immunocytochemical localization of basic fibro-blast growth factor in carcinomas and inflammatory lesions of the human digestive tract. Lab. Invest. 1993, 68:520.
127. Laiho M., Keski-Oja J. Growth factors in the regulation of pericellular proteolysis: A review. Cancer Res. 1989, 49:2533.
128. Moscatelli D., Presta M., Rifkin D.B. Purification of a factor from human placenta that stimulates capillary endothelial cell protease production, DNA synthesis, and migration. Proc. Natl. Acad. Sci. USA 1986, 83:2091.
129. Schweigerer L., Neufeld G., Friedman J., Abraham J.A., Fiddes J.C., Gospodarowicz D. Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth. Nature 1987, 325:257.
130. Klint P., Claesson-Welsh L. Signal transduction by fibroblast growth factor receptors. Front Biosci. 1999, 4:D165.
131. Burgess W.H., Dionne C.A., Kaplow J., Mudd R., Friesel R., Zilberstein A., Schlessinger J., Jaye M. Characterization and cDNA cloning of phospholipase C-gamma, a major substrate for heparin-binding growth factor 1 (acidic fibroblast growth factor)-activated tyrosine kinase. Mol. Cell. Biol. 1990, 10:4770.
132. Mohammadi M., Honegger A.M., Rotin D., Fischer R., Bellot F., Li W., Dionne C.A., Jaye M., Rubinstein M., Schlessinger J. A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast growth factor receptor (Flg) is a binding site for the SH2 domain of phospholipase C-gamma 1. Mol. Cell. Biol. 1991, 11:5068.
133. Zhan X., Plourde C., Hu X., Friesel R., Maciag T. Association of fibroblast growth factor receptor-1 with c-Src correlates with association between c-Src and cortactin. J. Biol. Chem. 1994, 269:20221.
134. Landgren E., Blume-Jensen P., Courtneidge S.A., Claesson-Welsh L. Fibroblast growth factor receptor-1 regulation of Src family kinases. Oncogene 1995, 10:2027.
135. Lewis T.S., Shapiro P.S., Ahn N.G. Signal transduction through MAP kinase cascades. Adv. Cancer Res. 1998, 74:49.
136. Kouhara H., Hadari Y.R., Spivak-Kroizman T., Schilling J., Bar-Sagi D., Lax I., Schlessinger J. A lipid-anchored Grb2-binding protein that links GFG-receptor activation to the Ras/MAPK signaling pathway. Cell 1997, 89:693.
137. Boilly B., Vercoutter-Edouart A.S., Hondermarck H., Nurcombe V., Le Bourhis X. FGF signals for cell proliferation and migration through different pathways. Cytokine Growth Factor Rev. 2000, 11:295.
138. Hirst D.G., Denekamp J. Tumour cell proliferation in relation to the vasculature. Cell Tissue Kinet. 1979, 12:31.
139. Sutherland R.M. Importance of critical metabolites and cellular interactions in the biology of microregions of tumors. Cancer 1986, 58:1668.
140. Hirst D.G., Hazlehurst J.L., Brown J.M. Changes in misonidazole binding with hypoxic fraction in mouse tumors. Int. J. Radiat. Oncol. Biol. Phys. 1985, 11:1349.
141. Dellacono F.R., Spiro J., Eisma R., Kreutzer D. Expression of basic fibroblast growth factor and its receptors by head and neck squamous carcinoma tumor and vascular endothelial cells. Am. J. Surg. 1997, 174:540.
142. Hughes C.J., Reed J.A., Cabal R., Huvos A.G., Albino A.P., Schantz S.P. Increased expression of basic fibroblast growth factor in squamous carcinogenesis of the head and neck is less prevalent following smoking cessation. Am. J. Surg. 1994, 168:381.
143. Partridge M., Kiguwa S., Luqmani Y., Langdon J.D. Expression of bFGF, KGF and FGF receptors on normal oral mucosa and SCC. Eur. J. Cancer B Oral Oncol. 1996, 32B:76.
144. Forootan S.S., Ke Y., Jones A.S., Helliwell T.R. Basic fibroblast growth factor and angiogenesis in squamous carcinoma of the tongue. Oral Oncol. 2000, 36:437.
145. Janot F., el-Naggar A.K., Morrison R.S., Liu T.J., Taylor D.L., Clayman G.L. Expression of basic fibroblast growth factor in squamous cell carcinoma of the head and neck is associated with degree of histologic differentiation. Int. J. Cancer 1995, 64:117.
146. Riedel F., Gotte K., Bergler W., Rojas W., Hormann K. Expression of basic fibroblast growth factor protein and its downregulation by interferons in head and neck cancer. Head Neck 2000, 22:183.
147. Ferrara N., Henzel W.J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 1989, 161:851.
148. Carmeliet P., Ferreira V., Breier G., Pollefeyt S., Kieckens L., Gertsenstein M., Fahrig M., Vandenhoeck A., Harpal K., Eberhardt C., Declercq C., Pawling J., Moons L., Collen D., Risau W., Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996, 380:435.
149. Ferrara N., Carver-Moore K., Chen H., Dowd M., Lu L., O'Shea K.S., Powell-Braxton L., Hillan K.J., Moore M.W. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996, 380:439.
150. Eriksson U., Alitalo K. Structure, expression and receptor-binding properties of novel vascular endothelial growth factors. Curr. Top. Microbiol. Immunol. 1999, 237:41.
151. Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999, 13:9.
152. Meyer M., Clauss M., Lepple-Wienhues A., Waltenberger J., Augustin H.G., Ziche M., Lanz C., Buttner M., Rziha H.J., Dehio C. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (F1t-1) receptor tyrosine kinases. EMBO J. 1999, 18:363.
153. Mustonen T., Alitalo K. Endothelial receptor tyrosine kinases involved in angiogenesis. J. Cell Biol. 1995, 129:895.
154. Shalaby F., Rossant J., Yamaguchi T.P., Gertsenstein M., Wu X.F., Breitman M.L., Schuh A.C. Failure of blood-island formation and vasculogenesis in F1k-1-deficient mice. Nature 1995, 376:62.
155. Fong G.H., Rossant J., Gertsenstein M., Breitman M.L. Role of the F1t-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995, 376:66.
156. Taipale J., Makinen T., Arighi E., Kukk E., Karkkainen M., Alitalo K. Vascular endothelial growth factor receptor-3. Curr. Top. Microbiol. Immunol. 1999, 237:85.
157. Wiesmann C., Fuh G., Christinger H.W., Eigenbrot C., Wells J.A., de Vos A.M. Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the F1t-1 receptor. Cell 1997, 91:695.
158. Hubbard S.R. Structural analysis of receptor tyrosine kinases. Prog. Biophys. Mol. Biol. 1999, 71:343.
159. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000, 103:211.
160. Guo D., Jia Q., Song H.Y., Warren R.S., Donner D.B. Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains: Association with endothelial cell proliferation. J. Biol. Chem. 1995, 270:6729.
161. Kroll J., Waltenberger J. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J. Biol. Chem. 1997, 272:32521.
162. Abedi H., Zachary I. Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells. J. Biol. Chem. 1997, 272:15442.
163. Gerber H.P., McMurtrey A., Kowalski J., Yan M., Keyt B.A., Dixit V., Ferrara N. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway: Requirement for F1k-1/KDR activation. J. Biol. Chem. 1998, 273:30336.
164. Hiratsuka S., Minowa O., Kuno J., Noda T., Shibuya M. F1t-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl. Acad. Sci. USA 1998, 95:9349.
165. Mattern J., Koomagi R., Volm M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br. J. Cancer 1996, 73:931.
166. Viglietto G., Maglione D., Rambaldi M., Cerutti J., Romano A., Trapasso F., Fedele M., Ippolito P., Chiappetta G., Botti G., et al. Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PIGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 1995, 11:1569.
167. Yoshiji H., Gomez D.E., Shibuya M., Thorgeirsson U.P. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res. 1996, 56:2013.
168. Brown L.F., Berse B., Jackman R.W., Tognazzi K., Manseau E.J., Senger D.R., Dvorak H.F. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res. 1993, 53:4727.
169. Brown L.F., Berse B., Jackman R.W., Tognazzi K., Manseau E.J., Dvorak H.F., Senger D.R. Incrased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am. J. Pathol. 1993, 143:1255.
170. Olson T.A., Mohanraj D., Carson L.F., Ramakrishnan S. Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res. 1994, 54:276.
171. Hashimoto M., Ohsawa M., Ohnishi A., Naka N., Hirota S., Kitamura Y., Aozasa K. Expression of vascular endothelial growth factor and its receptor mRNA in angiosarcoma. Lab. Invest. 1995, 73:859.
172. Plate K.H., Breier G., Weich H.A., Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992, 359:845.
173. Shweiki D., Itin A., Soffer D., Keshet E. Vascular endothelial growth factor induced by Hypoxia may mediate hypoxiainitiated angiogenesis. Nature 1992, 359:843.
174. Minchenko A., Bauer T., Salceda S., Caro J. Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. Lab. Invest. 1994, 71:374.
175. Brogi E., Wu T., Namiki A., Isner J.M. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation 1994, 90:649.
176. Shima D.T., Adamis A.P., Ferrara N., Yeo K.T., Yeo T.K., Allende R., Folkman J., D'Amore P.A. Hypoxic induction of endothelial cell growth factors in retinal cells: Identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol. Med. 1995, 1:182.
177. Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., Koos R.D., Semenza G.L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 1996, 16:4604.
178. Pertovaara L., Kaipainen A., Mustonen T., Orpana A., Ferrara N., Saksela O., Alitalo K. Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J. Biol. Chem. 1994, 269:6271.
179. Ben-Av P., Crofford L.J., Wilder R.L., Hla T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: A potential mechanism for inflammatory angiogenesis. FEBS Lett. 1995, 372:83.
180. Cohen T., Nahari D., Cerem L.W., Neufeld G., Levi B.Z. Interleukin 6 induces the expression of vascular endothelial growth factor. J. Biol. Chem. 1996, 271:736.
181. Warren R.S., Yuan H., Matli M.R., Ferrara N., Donner D.B. Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J. Biol. Chem. 1996, 271:29483.
182. Denhart B.C., Guidi A.J., Tognazzi K., Dvorak H.F., Brown L.F. Vascular permeability factor/vascular endothelial growth factor and its receptors in oral and laryngeal squamous cell carcinoma and dysplasia. Lab. Invest. 1997, 77:659.
183. Eisma R.J., Spiro J.D., Kreutzer D.L. Vascular endothelial growth factor expression in head and neck squamous cell carcinoma. Am. J. Surg. 1997, 174:513.
184. Salven P., Heikkila P., Anttonen A., Kajanti M., Joensuu H. Vascular endothelial growth factor in squamous cell head and neck carcinoma: Expression and prognostic significance. Mod. Pathol. 1997, 10:1128.
185. Toi M., Hoshina S., Takayanagi T., Tominaga T. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn. J. Cancer Res. 1994, 85:1045.
186. Gasparini G. Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 2000, 5:37.
187. Salven P., Ruotsalainen T., Mattson K., Joensuu H. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int. J. Cancer 1998, 79:144.
188. Maeda K., Chung Y.S., Ogawa Y., Takatsuka S., Kang S.M., Ogawa M., Sawada T., Sowa M. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996, 77:858.
189. Sauter E.R., Nesbit M., Watson J.C., Klein-Szanto A., Litwin S., Herlyn M. Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck. Clin. Cancer Res. 1999, 5:775.
190. Wakisaka N., Wen Q.H., Yoshizaki T., Nishimura T., Furukawa M., Kawahara E., Nakanishi I. Association of vascular endothelial growth factor expression with angiogenesis and lymph node metastasis in nasopharyngeal carcinoma. Laryngoscope 1999, 109:810.
191. Moriyama M., Kumagai S., Kawashiri S., Kojima K., Kakihara K., Yamamoto E. Immunohistochemical study of tumor angiogenesis in oral squamous cell carcinoma. Oral Oncol. 1997, 33:369.
192. Mineta H., Miura K., Ogino T., Takebayashi S., Misawa K., Ueda Y., Suzuki I., Dictor M., Borg A., Wennerberg J. Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas. Br. J. Cancer 2000, 83:775.
193. Mukhopadhyay D., Tsiokas L., Sukhatme V.P. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res. 1995, 55:6161.
194. Riedel F., Gotte K., Schwalb J., Schafer C., Hormann K. Vascular endothelial growth factor expression correlates with p53 mutation and angiogenesis in squamous cell carcinoma of the head and neck. Acta Otolaryngol. 2000, 120:105.
195. Dvorak H.F., Brown L.F., Detmar M., Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 1995, 146:1029.
196. Salven P., Manpaa H., Orpana A., Alitalo K., Joensuu H. Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin. Cancer Res. 1997, 3:647.
197. Linder C., Linder S., Munck-Wikland E., Strander H. Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bfgf) in patients with carcinoma and sarcoma. Anticancer Res. 1998, 18:2063.
198. Homer J.J., Anyanwu K., Ell S.R., Greenman J., Stafford N.D. Serum vascular endothelial growth factor in patients with head and neck squamous cell carcinoma. Clin. Otolaryngol. 1999, 24:426.
199. Riedel F., Gotte K., Schwalb J., Wirtz H., Bergler W., Hormann K. Serum levels of vascular endothelial growth factor in patients with head and neck cancer. Eur. Arch. Otorhinolaryngol. 2000, 257:332.
200. Gabrilovich D.I., Chen H.L., Girgis K.R., Cunningham H.T., Meny G.M., Nadaf S., Kavanaugh D., Carbone D.P. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Med. 1996, 2:1096.
201. Friedkin M., Roberts D. The enzymatic synthesis of nucleotides. II. Thymidine and related pyrimidine nucleosides. J. Biol. Chem. 1954, 207:257.
202. Zimmerman M., Seidenberg J. Deoxyribosyl transfer. I. Thymidine phosphorylase and nucleoside deoxyribosyltransferase in normal and malignant tissues. J. Biol. Chem. 1964, 239:2618.
203. Miyazono K., Okabe T., Urabe A., Takaku F., Heldin C.H. Purification and properties of an endothelial cell growth factor from human platelets. J. Biol. Chem. 1987, 262:4098.
204. Ishikawa F., Miyazono K., Hellman U., Drexler H., Wernstedt C., Hagiwara K., Usuki K., Takaku F., Risau W., Heldin C.H. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 1989, 338:557.
205. Reynolds K., Farzaneh F., Collins W.P., Campbell S., Bourne T.H., Lawton F., Moghaddam A., Harris A.L., Bicknell R. Association of ovarian malignancy with expression of platelet-derived endothelial cell growth factor. J. Natl. Cancer Inst. 1994, 86:1234.
206. Toi M., Hoshina S., Taniguchi T., Yamamoto Y., Ishitsuka H., Tominaga T. Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast cancer. Int. J. Cancer 1995, 64:79.
207. Takebayashi Y., Miyadera K., Akiyama S., Hokita S., Yamada K., Akiba S., Yamada Y., Sumizawa T., Aikou T. Expression of thymidine phosphorylase in human gastric carcinoma. Jpn. J. Cancer Res. 1996, 87:288.
208. Koukourakis M.I., Giatromanolaki A., Kakolyris S., O'Byrne K.J., Apostolikas N., Skarlatos J., Gatter K.C., Harris A.L. Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in non-small-cell lung cancer: Impact on tumour neoangiogenesis and survival. Br. J. Cancer 1998, 77:1696.
209. Takebayashi Y., Yamada K., Maruyama I., Fujii R., Akiyama S., Aikou T. The expression of thymidine phosphorylase and thrombomodulin in human colorectal carcinomas. Cancer Lett. 1995, 92:1.
210. Takebayashi Y., Akiyama S., Akiba S., Yamada K., Miyadera K., Sumizawa T., Yamada Y., Murata F., Aikou T. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J. Natl. Cancer Inst. 1996, 88:1110.
211. Fujieda S., Sunaga H., Tsuzuki H., Tanaka N., Saito H. Expression of platelet-derived endothelial cell growth factor in oral and oropharyngeal carcinoma. Clin. Cancer Res. 1998, 4:1583.
212. Fukuiwa T., Takebayashi Y., Akiba S., Matsuzaki T., Hanamure Y., Miyadera K., Yamada Y., Akiyama S. Expression of thymidine phosphorylase and vascular endothelial cell growth factor in human head and neck squamous cell carcinoma and their different characteristics. Cancer 1999, 85:960.
213. Giatromanolaki A., Fountzilas G., Koukourakis M.I., Arapandoni P., Theologi V., Kakolyris S., Georgoulias V., Harris A.L., Gatter K.C. Neo-angiogenesis in locally advanced squamous cell head and neck cancer correlates with thymidine phosphorylase expression and p53 nuclear oncoprotein accumulation. Clin. Exp. Metastasis 1998, 16:665.
214. Wolf G.T., Hudson J.L., Peterson K.A., Miller H.L., McClatchey K.D. Lymphocyte subpopulations infiltrating squamous carcinomas of the head and neck: Correlations with extent of tumor and prognosis. Otolaryngol. Head Neck Surg. 1986, 95:142.
215. + natural suppressor cells. Int. J. Cancer 1997, 74:69.
216. Mann E.A., Spiro J.D., Chen L.L., Kreutzer D.L. Cytokine expression by head and neck squamous cell carcinomas. Am. J. Surg. 1992, 164:567.
217. Yamamura M., Modlin R.L., Ohmen J.D., Moy R.L. Local expression of antiinflammatory cytokines in cancer. J. Clin. Invest. 1993, 91:1005.
218. Cohen R.F., Contrino J., Spiro J.D., Mann E.A., Chen L.L., Kreutzer D.L. Interleukin-8 expression by head and neck squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 1995, 121:202.
219. Lingen M.W., Polverini P.J., Bouck N.P. Retinoic acid induces cells cultured from oral squamous cell carcinomas to become anti-angiogenic. Am. J. Pathol. 1996, 149:247.
220. Chen Z., Colon I., Ortiz N., Callister M., Dong G., Pegram M.Y., Arosarena O., Strome S., Nicholson J.C., Van Waes C. Effects of interleukin-1 alpha, interleukin-1 receptor antagonist, and neutralizing antibody on proinflammatory cytokine expression by human squamous cell carcinoma lines. Cancer Res. 1998, 58:3668.
221. Woods K.V., El-Naggar A., Clayman G.L., Grimm E.A. Variable expression of cytolines in human head and neck squamous cell carcinoma cell lines and consistent expression in surgical specimens. Cancer Res. 1998, 58:3132.
222. Eisma R.J., Spiro J.D., Kreutzer D.L. Role of angiogenic factors: Coexpression of interleukin-8 and vascular endothelial growth factor in patients with head and neck squamous carcinoma. Laryngoscope 1999, 109:687.
223. Boyle J.O., Hakim J., Koch W., van der Riet P., Hruban R.H., Roa R.A., Correo R., Eby Y.J., Ruppert J.M., Sidransky D. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res. 1993, 53:4477.
224. Hegde P.U., Brenski A.C., Caldarelli D.D., Hutchinson J., Panje W.R., Wood N.B., Leurgans S., Preisler H.D., Taylor S.G.T., Caldarelli L., Coon J.S. Tumor angiogenesis and p53 mutations: Prognosis in head and neck cancer. Arch. Otolaryngol. Head Neck Surg. 1998, 124:80.
225. Dameron K.M., Volpert O.V., Tainsky M.A., Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994, 265:1582.
226. Dameron K.M., Volpert O.V., Tainsky M.A., Bouck N. The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin. Cold Spring Harb. Symp. Quant. Biol. 1994, 59:483.
227. Ravi D., Ramadas K., Mathew B.S., Nalinakumari K.R., Nair M.K., Pillai M.R. Angiogenesis during tumor progression in the oral cavity is related to reduced apoptosis and high tumor cell proliferation. Oral Oncol. 1998, 34:543.
228. Thomsen L.L., Lawton F.G., Knowles R.G., Beesley J.E., Riveros-Moreno V., Moncada S. Nitric oxide synthase activity in human gynecological cancer. Cancer Res. 1994, 54:1352.
229. Thomsen L.L., Miles D.W., Happerfield L., Bobrow L.G., Knowles R.G., Moncada S. Nitric oxide synthase activity in human breast cancer. Br. J. Cancer 1995, 72:41.
230. Rosbe K.W., Prazma J., Petrusz P., Mims W., Ball S.S., Weissler M.C. Immunohistochemical characterization of nitric oxide synthase activity in squamous cell carcinoma of the head and neck. Otolaryngol. Head Neck Surg. 1995, 113:541.
231. Morbidelli L., Chang C.H., Douglas J.G., Granger H.J., Ledda F., Ziche M. Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium. Am. J. Physiol. 1996, 270:H411.
232. Ziche M., Morbidelli L., Choudhuri R., Zhang H.T., Donnini S., Granger H.J., Bicknell R. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J. Clin. Invest. 1997, 99:2625.
233. Gallo O., Masini E., Morbidelli L., Franchi A., Fini-Storchi I., Vergari W.A., Ziche M. Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J. Natl. Cancer Inst. 1998, 90:587.
234. Brower V. Tumor angiogenesis: New drugs on the block. Nature Biotechnol. 1999, 17:963.
235. Giavazzi R., Albini A., Bussolino F., DeBraud F., Presta M., Ziche M., Costa A. The biological basis for antiangiogenic therapy. Eur. J. Cancer 2000, 36:1913.
236. Kerbel R.S. Tumor angiogenesis: Past, present and the near future. Carcinogenesis 2000, 21:505.
237. Bhargava P. Antiangiogenesis. Clinical Oncology 2000, 243. Churchill Livingstone, Ontario. 2nd Ed. M.D. Abeloff, J.O. Armitage, A.S. Lichter, J.E. Niederhuber (Eds.).
238. Lingen M.W. Angiogenesis in the development of head and neck cancer and its inhibition by chemopreventive agents. Crit. Rev. Oral. Biol. Med. 1999, 10:153.
239. Zou C.P., Clifford J.L., Xu X.C., Sacks P.G., Chambon P., Hong W.K., Lotan R. Modulation by retinoic acid (RA) of squamous cell differentiation, cellular RA-binding proteins, and nuclear RA receptors in human head and neck squamous cell carcinoma cell lines. Cancer Res. 1994, 54:5479.
240. Shalinsky D.R., Bischoff E.D., Gregory M.L., Gottardis M.M., Hayes J.S., Lamph W.W., Heyman R.A., Shirley M.A., Cooke T.A., Davies P.J., et al. Retinoid-induced suppression of squamous cell differentation in human oral squamous cell carcinoma xenografts (line 1483) in athymic nude mice. Cancer Res. 1995, 55:3183.
241. Sacks P.G., Harris D., Chou T.C. Modulation of growth and proliferation in squamous cell carcinoma by retinoic acid: A rationale for combination therapy with chemotherapeutic agents. Int. J. Cancer 1995, 61:409.
242. Liaudet-Coopman E.D., Berchem G.J., Wellstein A. In vivo inhibition of angiogenesis and induction of apoptosis by retinoic acid in squamous cell carcinoma. Clin. Cancer Res. 1997, 3:179.
243. Oikawa T., Hirotani K., Nakamura O., Shudo K., Hiragun A., Iwaguchi T. A Highly potent antiangiogenic activity of retinoids. Cancer Lett. 1989, 48:157.
244. Arensman R.M., Stolar C.J. Vitamin A effect on tumor angiogenesis. J. Pediatr. surg. 1979, 14:809.
245. Majewski S., Szmurlo A., Marczak M., Jablonska S., Bollag W. Inhibition of tumor cell-induced angiogenesis by retinoids, 1,25-dihydroxyvitamin D3 and their combination. Cancer Lett. 1993, 75:35.
246. Majewski S., Szmurlo A., Marczak M., Jablonska S., Bollag W. Synergistic effect of retinoids and interferon alpha on tumor-induced angiogenesis: Anti-angiogenic effect on HPV-harboring tumor-cell lines. Int. J. Cancer 1994, 57:81.
247. Majewski S., Marczak M., Szmurlo A., Jablonska S., Bollag W. Retinoids interferon alpha, 1,25-dihydroxyvitamin D3 and their combination inhibit angiogenesis induced by non-HPV-harboring tumor cell lines: RAR alpha mediates the antiangiogenic effect of retinoids. Cancer Lett. 1995, 89:117.
248. Liaudet-Coopman E.D.E., Wellstein A. Regulation of gene expression of a binding protein for fibroblast growth factors by retinoic acid. J. Biol. Chem. 1996, 271:21303.
249. Maheshwari R.K., Srikantan V., Bhartiya D., Kleinman H.K., Grant D.S. Differential effects of interferon gamma and alpha on in vitro model of angiogenesis. J. Cell. Physiol. 1991, 146:164.
250. Ruszczak Z., Detmar M., Imcke E., Orfanos C.E. Effects of rIFN alpha, beta, and gamma on the morphology, proliferation, and cell surface antigen expression of human dermal microvascular endothelial cells in vitro. J. Invest. Dermatol. 1990, 95:693.
251. Saiki I., Sato K., Yoo Y.C., Murata J., Yoneda J., Kiso M., Hasegawa A., Azuma I. Inhibition of tumor-induced angiogenesis by the administration of recombinant interferon-gamma followed by a synthetic lipid-A subunit analogue (GLA-60). Int. J. Cancer 1992, 51:641.
252. Hong W.K., Lippman S.M., Itri L.M., Karp D.D., Lee J.S., Byers R.M., Schantz S.P., Kramer A.M., Lotan R., Peters L.J., et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 1990, 323:795.
253. Lippman S.M., Glisson B.S., Kavanagh J.J., Lotan R., Hong W.K., Paredes-Espinoza M., Hittelman W.N., Holdener E.E., Krakoff I.H. Retinoic acid and interferon combination studies in human cancer. Eur. J. Cancer. 1993, 29A:S9.
254. Moore D.M., Kalvakolanu D.V., Lippman S.M., Kavanagh J.J., Hong W.K., Borden E.C., Paredes-Espinoza M., Krakoff I.H. Retinoic acid and interferon in human cancer: Mechanistic and clinical studies. Semin. Hematol. 1994, 31:31.
255. Lingen M.W., Polverini P.J., Bouck N.P. Retinoic acid and interferon alpha act synergistically as antiangiogenic and antitumor against human head and neck squamous cell carcinoma. Cancer Res. 1998, 58:5551.
256. Ingber D., Fujita T., Kishimoto S., Sudo K., Kanamaru T., Brem H., Folkman J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990, 348:555.
257. Yanase T., Tamura M., Fujita K., Kodama S., Tanaka K. Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res. 1993, 53:2566.
258. Gleich L.L., Zimmerman N., Wang Y.O., Gluckman J.L. Angiogenic inhibition for the treatment of head and neck cancer. Anticancer Res. 1998, 18:2607.
259. Ueda N., Kamata N., Hayashi E., Yokoyama K., Hoteiya T., Nagayama M. Effects of an anti-angiogenic agent, TNP-470, on the growth of oral squamous cell carcinomas. Oral Oncol. 1999, 35:554.
260. Hori A., Sasada R., Matsutani E., Naito K., Sakura Y., Fujita T., Kozai Y. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res. 1991, 51:6180.
261. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362:841.
262. Olson K.A., Fett J.W., French T.C., Key M.E., Vallee B.L. Angiogenin antagonists prevent tumor growth in vivo. Proc. Natl. Acad. Sci. USA 1995, 92:442.
263. Braddock P.S., Hu D.E., Fan T.P., Stratford I.J., Harris A.L., Bicknell R. A structure-activity analysis of antagonism of the growth factor and angiogenic activity of basic fibroblast growth factor by suramin and related polyanions. Br. J. Cancer 1994, 69:890.
264. Takano S., Gately S., Neville M.E., Herblin W.F., Gross J.L., Engelhard H., Perricone M., Eidsvoog K., Brem S. Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res. 1994, 54:2654.
265. Myers C., Cooper M., Stein C., LaRocca R., Walther M.M., Weiss G., Choyke P., Dawson N., Steinberg S., Uhrich M.M., et al. Suramin: A novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J. Clin. Oncol. 1992, 10:881.
266. Tanaka N.G., Sakamoto N., Inoue K., Korenaga H., Kadoya S., Ogawa H., Osada Y. Antitumor effects of an antiangiogenic polysaccharide from an Arthrobacter species with or without a steroid. Cancer Res. 1989, 49:6727.
267. Maione T.E., Gray G.S., Petro J., Hunt A.J., Donner A.L., Bauer S.I., Carson H.F., Sharpe R.J. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990, 247:77.
268. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., Lane W.S., Cao Y., Sage E.H., Folkman J. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994, 79:315.
269. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., Folkman J. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277.
270. Brooks P.C., Montgomery A.M., Rosenfeld M., Reisfeld R.A., Hu T., Klier G., Cheresh D.A. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994, 79:1157.
271. Brown P.D., Giavazzi R. Matrix metalloproteinase inhibition: A review of anti-tumour activity. Ann. Oncol. 1995, 6:967.
272. Tamargo R.J., Bok R.A., Brem H. Angiogenesis inhibition by minocycline. Cancer Res. 1991, 51:672.
273. Mueller B.M., Yu Y.B., Laug W.E. Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid mice. Proc. Natl. Acad. Sci. USA 1995, 92:205.
274. Gagliardi A.R., Collins D.C. Inhibition of angiogenesis by aurintricarboxylic acid. Anticancer Res. 1994, 14:475.
275. Vukanovic J., Passaniti A., Hirata T., Traystman R.J., Hartley-Asp B., Isaacs J.T. Antiangiogenic effects of the quinoline-3-carboxamide linomide. Cancer Res. 1993, 53:1833.
276. Gagliardi A., Collins D.C. Inhibition of angiogenesis by antiestrogens. Cancer Res. 1993, 53:533.
277. Matsubara T., Saura R., Hirohata K., Ziff M. Inhibition of human endothelial cell proliferation in vitro and neovascularization in vivo by D-penicillamine. J. Clin. Invest. 1989, 83:158.
278. Fotsis T., Pepper M., Adlercreutz H., Fleischmann G., Hase T., Montesano R., Schweigerer L. Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc. Natl. Acad. Sci. USA 1993, 90:2690.
279. D'Amato R.J., Loughnan M.S., Flynn E., Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA 1994, 91:4082.
280. Sidky Y.A., Borden E.C. Inhibition of angiogenesis by interferons: Effects on tumor- and lymphocyte-induced vascular responses. Cancer Res. 1987, 47:5155.
281. Voest E.E., Kenyon B.M., O'Reilly M.S., Truitt G., D'Amato R.J., Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J. Natl. Cancer Inst. 1995, 87:581.
282. Oikawa T., Hirotani K., Ogasawara H., Katayama T., Nakamura O., Iwaguchi T., Hiragun A. Inhibition of angiogenesis by vitamin D3 analogues. Eur. J. Pharmacol. 1990, 178:247.
283. Shokravi M.T., Marcus D.M., Alroy J., Egan K., Saornil M.A., Albert D.M. Vitamin D inhibits angiogenesis in transgenic murine retinoblastoma. Invest. Ophthalmol. Vis. Sci. 1995, 36:83.
284. Ziche M., Morbidelli L., Masini E., Amerini S., Granger H.J., Maggi C.A., Geppetti P., Ledda F. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J. Clin. Invest. 1994, 94:2036.
285. Weinstat-Saslow D.L., Zabrenetzky V.S., VanHoutte K., Frazier W.A., Roberts D.D., Steeg P.S. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res. 1994, 54:6504.
286. Greer P., Haigh J., Mbamalu G., Khoo W., Bernstein A., Pawson T. The Fps/Fes protein-tyrosine kinase promotes angiogenesis in transgenic mice. Mol. Cell. Biol. 1994, 14:6755.